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Fragile X syndrome (FXS) is the most common known genetic form of intellectual disability and autism spectrum disorders.
FXS patients suﬀer a broad range of other neurological symptoms, including hyperactivity, disrupted circadian activity cycles,
obsessive-compulsive behavior, and childhood seizures. The high incidence and devastating eﬀects of this disease state make
ﬁnding eﬀective pharmacological treatments imperative. Recently, reports in both mouse and Drosophila FXS disease models have
indicated that the tetracycline derivative minocycline may hold great therapeutic promise for FXS patients. Both models strongly
suggest that minocycline acts on the FXS disease state via inhibition of matrix metalloproteinases (MMPs), a class of zinc-
dependent extracellular proteases important in tissue remodeling and cell-cell signaling. Recent FXS clinical trials indicate that
minocycline may be eﬀective in treating human patients. In this paper, we summarize the recent studies in Drosophila and mouse
FXS disease models and human FXS patients, which indicate that minocycline may be an eﬀective FXS therapeutic treatment, and
discuss the data forming the basis for the proposed minocycline mechanism of action as an MMP inhibitor.
1.Introduction
FragileXsyndrome(FXS),themostcommonheritablecause
of intellectual disability and autism spectrum disorders [1],
has a prevalence of roughly 1 in 4000 males and 1 in 6000
females [2, 3]. While a hallmark of FXS is low IQ (∼40),
patients present with a wide spectrum of behavioral, phys-
ical, and neurological symptoms [4–6]. Behavioral problems
include hyperactivity and hypersensitivity to sensory stim-
uli, anxiety and mood disorders, disrupted sleep patterns,
defects in cognitive learning and memory consolidation, and
impaired social skills [1, 4, 5, 7–14]. Often, a speech deﬁcit
is the ﬁrst symptom leading to a FXS clinical diagnosis
[4, 5]. Although there are usually not signiﬁcant non-
neurological medical impairments associated with the syn-
drome, FXS patients typically display male macroorchidism,
macrocephaly with prominent ears and a long, thin face,
joint hypermobility, and ﬂat feet [4, 5, 15–17]. Elevated
electroencephalogram (EEG) activity is characteristic, and
epileptic seizures are present in ∼20% of FXS patients,
typically with remittance by adulthood [18].
FXS is caused by loss of the fragile X mental retardation 1
(FMR1) gene product, FMRP [19], typically due to expan-
sion (>200) of the CGG trinucleotide repeat in the 5 -
untranslated gene region, leading to subsequent hyperme-
thylation and gene silencing [20]. FMRP is an mRNA-
binding protein known to regulate mRNA stability, traf-
ﬁcking, and translation [21–26], with roles in the activity-
dependent regulation of synaptic development and plasticity
[26–33]. Numerous studies support the “mGluR theory
of FXS” that suggests enhanced group 1 metabotropic
glutamate receptor 5 (mGluR5) signaling is responsible for
deﬁcits in synaptogenesis, dendritic spine morphology, long-
term potentiation (LTP) and depression (LTD) in the
disease state [5, 27, 28, 30–32, 34–43]. Consequently, many
studies have focused on mGluR inhibitors, such as 2-
methyl-6-phenylethynyl-pyridine (MPEP), as a therapeutic
intervention for FXS [31, 38–40, 43–47], with considerable2 Neural Plasticity
success. For example, in the Drosophila disease model, MPEP
eﬀectively prevents cellular synaptic deﬁcits and behavioral
learning and memory impairments [31, 42, 45, 46]. While
some mGluR inhibitors cannot be used in FXS patient
treatment due to toxicity and bioavailability limitations (e.g.,
MPEP), other drugs, such as the selective mGluR5 inhibitor
fenobam, are currently in human clinical trials [48, 49].
Lithium, an inhibitor of GSK3β, a downstream eﬀector of
mGluR5 signaling, is also being taken to clinical trials with
promising results as a potential FXS therapeutic treatment
[50].
In addition to the promise of mGluR5 pathway interven-
tions, several recent reports suggest minocycline as another
potential avenue of FXS therapeutic treatment [51–54]. Used
for decades as an antibiotic and acne treatment, the second-
generation,semisynthetictetracyclinederivativeminocycline
has a long half-life, highly lipophilic characteristics, and
easily crosses the blood-brain barrier [55]. In addition to
its antibiotic actions, minocycline also functions as an anti-
inﬂammatory agent via inhibition of several molecules,
including COX-2, iNOS, and p38 MAPK, and as an anti-
apoptoticagentviainhibitionofcaspases,amongmanyother
putative modes of action [55, 56]. Central to its role in FXS,
minocycline is known to inhibit matrix metalloproteinases
(MMPs), a family of secreted and membrane-tethered
zinc-dependent extracellular proteases with roles in tissue
remodeling and intercellular signaling [57–60]. Functioning
through one or more of these modes of action, minocycline
has been shown to have neuroprotective eﬀects [55]a n d
has been previously suggested to be useful in the treatment
of several neurodegenerative diseases, including multiple
sclerosis [61], amyotrophic lateral sclerosis (ALS) [62, 63],
Huntington’s disease [64], Parkinson’s disease [65], and
Alzheimer’s disease [66].
In the FXS disease state, several recent studies have
proposed that minocycline exerts its therapeutic eﬀects via
MMP inhibition [51, 53]. In humans, a diverse array of
at least 24 MMPs functions to cleave components of the
extracellular matrix (ECM), including both secreted and cell
membraneproteins[57–59].Ingeneral,MMPscontainapro
domain that is cleaved to activate the extracellular protease,
an enzymatic zinc-containing catalytic domain, a linker
domain, and a hemopexin domain [57–59]. MMPs are part
of the metzincin family of proteases, named for a conserved
methionine residue and zinc in the protease catalytic sites,
which includes ADAMs (a disintegrin and metallopro-
teinase) and ADAM proteases with thrombospondin motifs
(ADAMTSs) [57–59, 67]. In the central nervous system,
MMPs have been implicated in axonal guidance, synaptoge-
nesis, neurotransmission, synaptic plasticity, and behavioral
learning [57, 58, 67]. MMPs are endogenously inhibited by
tissue inhibitors of MMPs (TIMPs), with 4 family members
in humans [68, 69]. Along with MMPs, TIMPs are also
expressed in the central nervous system, where they also
regulate synaptic mechanisms and behavioral outputs [67–
69].
In this paper, we review recent evidence that minocycline
acts as an eﬀective therapeutic treatment in FXS genetic
animal models and human FXS patient clinical trials.
We then summarize current data supporting an “MMP
inhibitionmechanism”bywhichminocyclinemayremediate
the FXS disease state. Finally, we consider possible pathways
through which the MMP/TIMP and FMRP pathways could
intersect in the formation of FXS pathogenesis.
2. MinocyclineinFragile X AnimalModels
Minocycline was ﬁrst revealed as a possible FXS therapeutic
treatment in the mouse disease model [51]. The FMR1
knockout (KO) mouse is a well-validated model of the
human disease state [30, 40, 51, 71, 72], which displays
macroorchidism, hyperactivity, and some learning/memory
deﬁcits[71–73].Aswithcorticalpostsynapticdendriticspine
morphogenesis defects in FXS patient brain autopsies [74,
75], FMR1 KO mice exhibit an immature dendritic spine
proﬁle with more long, thin ﬁlopodia-like spines and a
proportional lack of mature short, stubby, mushroom-like
spines [76–79]. This synaptic maturation/overgrowth defect
h a sb e e nr e p o r t e dt ov a r yi ns e v e r i t y / p e n e t r a n c ei nd i ﬀerent
brain regions and may be developmentally transient, with
the defect being most prominent during neural circuit
reﬁnement stages of early postnatal development [80, 81].
The dendritic spine phenotype of FMR1 KO mice has been
linked with defects in postsynaptic group 1 mGluR signaling
activity, as with defects in synaptic plasticity [82]. This
postsynaptic dendritic spine defect has long been considered
theFXSneuroanatomicalhallmarkandwasthelogicalchoice
to ﬁrst assay the eﬀects of minocycline treatment.
In 2009, Bilousova and colleagues provided the ﬁrst evi-
dence for the therapeutic eﬀectiveness of minocycline in the
FMR1 KO mouse with a thorough examination of dendritic
spine proﬁles of hippocampal neurons both in vitro and
in vivo [51]. This study showed that 20μMm i n o c y c l i n e
promoted maturation of dendritic spines in control hip-
p o c a m p a ln e u r o n a lc u l t u r e s .I nFMR1 KO neurons, minocy-
clinetreatmentinculture(20μMfor17hours)orfedtomice
(30mg/kg/day in drinking water) shifted the immature den-
dritic spine proﬁles towards normal dendritic spine proﬁles
(Table 1).Itisimportanttonotethatnochangewasreported
in dendritic spine length or the total number of spines
between FMR1 KO untreated and treated conditions; rather,
there was solely a proportional shift of the number of imma-
ture to mature spines upon minocycline treatment [51].
Following this neuroanatomical analysis, the same study
examined the eﬀect of minocycline treatment on FMR1 KO
mouse behavior [51]. Minocycline was again fed to newborn
mice via their drinking water at levels of 30mg/kg/day. At 3
weeks of age, treated FMR1 KO mice were found to be less
anxious in an elevated plus maze assay (Table 1). Moreover,
minocyclinetreatmentresultedinbettermemoryinapassive
Y maze, compared to untreated FMR1 KO mice [51].
Additionally, a follow-up study was very recently conducted
by this same group [70]. In FMR1 KO adult male mice, it
was found that the rate of ultrasonic vocalizations (USVs)
produced during mating is reduced. No other acoustic
property deﬁcits were identiﬁed. Interestingly, minocycline
treatment restored a normal rate of USVs in the FMR1 KONeural Plasticity 3
Table 1: Summary of recent minocycline treatment trials in Drosophila and mouse disease models, and human clinical studies. The columns
display the systems, minocycline dosages, phenotypes tested, treatment outcomes and side eﬀects.
Model Dosage Phenotypes tested Treatment eﬀects Side eﬀects Study
Drosophila 20μM in larvae;
1mM in adult (oral feeding)
Synpatic structure of NMJ,
sLNv, and MB neurons
Prevention of all
neuroanatomical defects None
Siller and
Broadie, 2011
[53]
Mouse 20μM for 17hrs in vitro;
30mg/kg/day in vivo
Immature dendritic spine
proﬁles, anxiety, memory
defects, decreased rate of
USVs
More mature dendritic
spine proﬁles, less anxious,
memory improvements,
increased rate of USVs
More mature
dendritic spines
Bilosuova et
al., 2009; [51]
Rotschafer et
al., 2012 [70]
Human
50mg BID
(low dose)
100mg BID
(high dose)
Behavioral symptoms
Better language and social
communication skills, less
anxiety, more attentive;
Better irritability,
stereotypy, hyperactivity,
inappropriate speech
subscales on ABC-C
GI issues,
diarrhea, loss of
appetite,
dizziness,
headaches
Utari et al.,
2010; [54]
Paribello et al.,
2010 [52]
mouse (Table 1). Thus, minocycline was shown to be eﬀec-
tive at ameliorating both neuroanatomical and behavioral
FXS defects in the mouse disease model.
Recently, a study employing the Drosophila FXS disease
modelcorroboratedandexpandedthesedata,reinforcingthe
therapeutic potential of minocycline treatment [53]. Over
more than a decade of research, the Drosophila system has
been ﬁrmly established as a highly validated model of the
human disease state [25, 26, 31, 42–47, 83–99]. Drosophila
contains a single FMR1 homolog, dFMR1, compared to the
three Fragile X family genes present in mammals (FMR1,
FXR1, and FXR2). Only human FMR1 rescues the broad
range of neurological phenotypes caused by dFMR1 KO,
with human FXR1/2 having no activity, showing that FMR1
function has been evolutionarily conserved and that human
FMR1 requirements can be eﬀectively dissected in the
Drosophila FXS disease model [84, 99]. Like human patients
and the mouse model, dFMR1 KO ﬂies exhibit synaptic
overgrowth and synaptic immaturity in a range of neu-
ral circuits, including motor neurons [84, 86, 99], clock
neurons [84, 87, 88, 99], and learning/memory neurons
[26, 42]. Likewise mimicking the human disease condition,
dFMR1 null animals display macroorchidism and deﬁcits in
spermatogenesis, hyperactivity and circadian arrhythmicity,
and strong deﬁcits in learning formation and memory
consolidation [46, 83, 85, 87, 88, 92]. The breadth and FXS
disease relevance of these phenotypes makes Drosophila an
excellent system to examine minocycline’s eﬀectiveness in
treating the disease state.
In 2011, Siller and Broadie provided a follow-up study
examining the therapeutic eﬀectiveness of minocycline in
the dFMR1 KO in a thorough examination of synaptic
architecture in a range of disparate neural circuit types [53].
Synapse structure was analyzed in three locations: (1) the
well-characterized glutamatergic neuromuscular junction
(NMJ) in the peripheral musculature, (2) the pigment
dispersing factor (PDF) neuropeptidergic small ventrolateral
(sLNv) clock neurons in the central brain, and (3) Kenyon
cellneurons of the brain mushroom body (MB) learning and
memory center (Table 1). In all three circuit types, the
dFMR1 KO displays the same characteristic synaptic over-
growth and overelaboration, including an expanded synaptic
arbor domain, increased synaptic branching, and increased
supernumerary synaptic boutons with prominent struc-
turally immature synaptic sites [25, 26, 42, 47, 86, 87].
Minocycline was fed to dFMR1 KO mutants in their food
during larval development in the range of 2–20μMa n dt o
adults at the higher dosage of 1mM (Table 1), resulting in
a dosage-dependent improvement of synaptic architecture
towards the wildtype state [53]. Interestingly, the CNS
synaptic deﬁcits responded better to minocycline treatment
than the NMJ defects, although the reason for this diﬀerence
is currently unknown. At the NMJ, minocycline treatment
completely prevented the accumulation of immature synap-
tic boutons and partially prevented the overabundance of
mature boutons, but had no eﬀect on the defect in synaptic
branching in dFMR1 KOs [53]. In the brain, both in clock
neurons and in MB Kenyon cells, minocycline treatment
bothpreventedtheexcesssynapticbranchingandcompletely
rescued the overelaboration of synaptic boutons in dFMR1
KOs (Table 1). Unlike the mouse study, the Drosophila
study found no eﬀect of minocycline treatment on wild-
type synaptic architecture [53]. Moreover, the Drosophila
study contained no behavioral analyses. However, at a
neuroanatomical level, the Drosophila study corroborates the
ﬁndings of the mouse study and adds further evidence for
the eﬀectiveness of minocycline as a broad-spectrum FXS
therapeutic treatment in multiple classes of neural circuits
[51, 53].
3. MinocyclineinFragile X Patients
Taken together, the two animal model studies strongly
suggest minocycline may be an eﬀective FXS treatment.
However, the obvious question still remains: does the drug
eﬀect translate to human FXS patients? In 2010, two studies
began to provide insight into this question with early clinical
trials [52, 54]. Utari and colleagues studied 50 FXS patients,
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the safety of the drug as a FXS treatment [54]. Of the 50
patients examined, 21 reported side eﬀects, with the most
commonbeinggastrointestinalproblems,includingdiarrhea
and loss of appetite (Table 1). Most patients reported side
eﬀects as mild. One patient did experience coloring of the
nails, but none reported tooth discoloration. Of the FXS
patients followed throughout the course of the study, most
displayed improvements in several areas, including language,
attention, social communication, and anxiety [54]. A small
subset of patients exhibited worsening in two areas: hyper-
activity and moodiness (Table 1). Thus, this study suggests
minocycline may be eﬀective in FXS treatment with only
mild side eﬀects, and the results warrant a followup,
controlled study to more closely examine minocycline eﬀec-
tiveness.
Paribello and colleagues performed an open-label, add-
on minocycline treatment trial with 19 FXS patients aged
13–32 years followed for an 8-week treatment period [52].
One patient dropped out due to side eﬀects, and two other
patients developed asymptomatic seroconversion of antin-
uclear antibodies, a diagnostic in autoimmune disorders.
None of the other patients reported serious side eﬀects that
were attributed to the minocycline treatment, although
dizziness, headaches, sleepiness, and diarrhea were reported
as mild side eﬀects (Table 1). In this trial, signiﬁcant
improvements occurred in behavioral outcomes using the
Aberrant Behavior Checklist-Community Edition (ABC-C)
[52]. Four out of ﬁve subscale scores showed signiﬁcant
improvement, including the irritability subscale, which was
used as the primary outcome measure, and stereotypy,
hyperactivity, and inappropriate speech subscales, which
were employed as secondary outcome measures (Table 1).
Positive results using the clinical global improvement scale
(CGI) and the visual analog scale for behavior (VAS) as
measureswerealsoreportedforthemajorityofminocycline-
treated FXS patients [52]. Interestingly, given the choice
to extend minocycline treatment for 1 year, 18 of the 19
families independently decided to continue treatment based
on their perceptions of behavioral improvements. Taken
together with the Utari study, both sets of data strongly
suggest that minocycline is a relatively safe and potentially
eﬀective treatment for FXS patients [52, 54]. However, a
double-blind, placebo-controlled clinical treatment trial is
still necessary to provide concrete evidence that minocycline
is a positive and eﬀective FXS therapy.
4. Mechanismof Action: MMP Inhibition
The 2009 mouse FXS model study provides good evidence
that minocycline acts through inhibition of secreted matrix
metalloproteinase-9 (MMP-9) [51]. In other neurological
disorders, such as multiple sclerosis, minocycline has sim-
ilarly been found to be eﬀective as an MMP-9 inhibitor
[55]. Bilousova and colleagues performed both Western
Blot and gel zymography analyses to assess diﬀerences in
MMP-9 levels and enzymatic (gelatinase) activity in the
mouse hippocampus [51]. In FMR1 KO (P7) mice, levels
of active MMP-9 as well as MMP-9 gelatinase activity were
bothincreasedcomparedtocontrols(Figure 1).Importantly,
minocycline treatment of the FMR1 KO decreased both
hippocampal active MMP-9 protein levels and hippocampal
gelatinaseactivitytowardsthewildtypecondition[51].Inter-
estingly, MMP-9 treatment of wildtype hippocampal cell
cultures induced immature dendritic spine proﬁles with
a greater proportion of long, thin ﬁlopodia-like dendritic
spines,mimicking theFMR1KOstate[51],aﬁndingthathas
sincebeenvalidatedviageneticmethods[100].Together,this
evidence suggests that upregulation of secreted active MMP-
9isanovelaspectofthemolecularpathologyofFXSandthat
MMP-9inhibitionisthemechanismofactionofminocycline
in alleviating FXS phenotypes (Figure 1).
In the follow-up Drosophila study, Siller and Broadie
greatly extended testing of this MMP hypothesis, taking
advantage of the ﬂy’s relative genetic simplicity (2 MMPs
in Drosophila compared to 24 in mammals; 1 TIMP in
Drosophila compared to 4 in mammals) [53, 57, 58, 60, 101].
The two Drosophila MMPs include secreted MMP-1 and
membrane anchored MMP-2, with a good antibody probe
available for MMP-1 only. MMP-1 expression levels and
gelatinase activity showed no signiﬁcant diﬀerences in the
dFMR1 KO compared to control, at least at the NMJ synapse
with immunocytochemistry and in situ zymography and in
whole-brain Western Blots (Figure 1)[ 53]. Nevertheless, to
begin to test the MMP hypothesis, the endogenous TIMP
inhibitor was genetically overexpressed in the dFMR1 KO
background to mimic the proposed minocycline eﬀect. At
the NMJ, TIMP overexpression was highly eﬃcacious in
suppressing the synaptic structural overelaboration charac-
terizing the dFMR1 KO, restoring the synaptic branching
and excess mature and immature bouton formation to the
wildtype condition [53]. Conversely, TIMP overexpression
causes early developmental lethality and tracheal deforma-
tions prior to death [60, 102, 103], and dFMR1 removal
bidirectionally suppressed these TIMP overexpression phe-
notypes. Importantly, a dFMR1; MMP-1 double KO mutant
displayed the same reciprocal suppression of phenotypes,
with prevention of dFMR1 KO synaptic architecture defects
and rescue of MMP-1 KO tracheal defects and early lethality
[53]. Together, these data provide excellent evidence for
a speciﬁc genetic interaction between the TIMP/MMP-1
and FMRP pathways (Figure 1). Taken with the previous
mouse FXS model study showing speciﬁc upregulation of
secreted MMP-9, reduced upon minocycline treatment, the
combined data set strongly suggests that minocycline is
inhibiting MMPs to exert its alleviatory actions on FXS
phenotypes [51, 53].
A critical question is to determine how the FMRP and
TIMP/MMP pathways intersect (Figure 1). FMRP is best
known as a negative translational regulator, and, therefore,
it is possible that FMRP directly inhibits MMP expression,
resulting in MMP upregulation in the FXS disease state.
Based on known FMRP functions, this interaction could
happen at the level of regulating MMP mRNA stability
or translation, or FMRP could secondarily inﬂuence MMP
protein function, secretion, or localization via acting on
MMP-interacting proteins (Figure 1). However, numerous
more indirect interactions between the two pathways are alsoNeural Plasticity 5
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MMP-dependent plasticity
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cadherins,
β-dystroglycans,
brevican, tenascin-R
Figure 1: Schematic of potential interaction mechanisms between FMRP and MMPs. FMRP may more directly regulate MMPs at the level
of transcript stability, translation, or protein function. FMRP may more indirectly convergently interact with MMPs in the regulation of
extracellular matrix (ECM) components and their receptors, via the endogenous TIMP regulatory mechanism, or via glutamate receptor
(GluR) signaling.
possible. FXS is a disease of enhanced glutamate receptor
signaling, associated with defects in synaptic morphogenesis
and plasticity (LTD/LTP) [35, 37]. Several studies have
shown that NMDA glutamate receptor signaling causes local
MMP-9release,leadingtoMMP-mediatedsynapticplasticity
events[104–106],presumablyviaextracellularproteins,such
as integrins, laminins, cadherins, β-dystroglycan, brevican,
and tenascin-R, which have all been implicated in hip-
pocampal LTP [57, 58, 67]( Figure 1). Indeed, recent work
implicates integrin β1 signaling as the mechanism by which
MMP-9-mediated changes in dendritic spine morphology
occur [100]. Furthermore, MMP-dependent synapse remod-
eling can be blocked by NMDA receptor inhibitors, and
NMDA receptor activity has been shown to increase MMP-
9 activity, suggesting another possible link [58]. Moreover,
MMPs play roles in axonal-dendritic structural remodeling
[58, 67]; for example, with MMP-9 present in mammalian
dendritic spines and MMP-1 present at the Drosophila gluta-
matergic NMJ [53, 107, 108]. MMP-9 KO mice display deﬁ-
cienciesinhippocampalLTP,andotherchanges,forexample,
after spinal cord injury, can induce elevated gelatinasez
activity, showing that careful control of MMP expression
levelsiscriticaltosynapticregulation[105,109].Inaddition,
MMP inhibition may lead to TIMP signaling changes due
to decreased levels of MMP-bound TIMP versus increased
levels of free unbound TIMP [110]. For example, the balance
between MMP-7 and TIMP-1 was recently shown to be
important for pro-nerve growth factor (NGF) cleavage and
neuroprotection following kainite-induced seizures [111],
which could possibly provide a link with seizure manifesta-
tions in FXS patients. Thus, while it is unclear how the MMP
and FMRP pathways intersect, it is clear that a number of
intriguing possibilities need to be explored (Figure 1).
5. Conclusions andFutureDirections
FXS is a devastating neurological disease characterized by
a broad spectrum of cellular and behavioral symptoms [4,
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inhibitors as a potential avenue of disease treatment [31, 45–
47], a signiﬁcant amount of new evidence from Drosophila
[53], mouse [51], and human studies [52, 54] suggests that
the common tetracycline derivative minocycline may be
an e wa n dh i g h l ye ﬀective treatment alternative (Table 1).
These recent reports indicate that minocycline may be a
broad-spectrum treatment with only mild side eﬀects. The
clear next step is to pursue a double-blind, placebo-
controlled FXS clinical trial of minocycline eﬀectiveness.
Importantly, it may be critical to test minocycline in young
children as it is probable that treatment eﬀectiveness may
be linked, in part, to developmentally transient events of
neural circuit formation and/or reﬁnement. Of course, it is
to be hoped that the inherent plasticity of the nervous system
will also make adult minocycline treatments eﬀective. Thus,
minocycline holds the real possibility of being an accessible
and cost-eﬀective broad treatment for the disease. Impor-
tantly, minocycline has long been FDA approved, greatly
facilitating its rapid dissemination to the FXS community.
This is indeed an exciting development for families aﬄicted
by this devastating neurological disease.
Both Drosophila and mouse studies point toward MMP
inhibition being the mechanism of minocycline action in6 Neural Plasticity
FXS [51, 53]. However, another possibility that must be con-
sideredarisesfromthefactthatminocyclinealsofunctionsas
an antibiotic by inhibiting bacterial translation, and a similar
function could be predicted to antagonize the eﬀect of losing
FMRP translational repression, causing elevated translation
[21]. Although this should not be a consideration at the
levelsofminocyclineusedintherecentFXSstudies(Table 1),
which are the same dosages as used for treatment of acne
and bacterial infections, such as neurosyphilis [112, 113], it
remains a strong possibility to be investigated as potentially
FXS patients may be more sensitive toward minocycline
treatment than healthy individuals. Signiﬁcant research into
minocycline’s eﬀects on eukaryotic ribosomes, especially in
FXS, has not been done and must be performed extensively
to determine if the minocycline mechanism of action is
through its ability to regulate translation. In addition, the
available evidence does not rule out the possibility of other
mechanisms of minocycline action, such as p53 MAPK
regulation [55, 114, 115]. Nevertheless, the recent Drosophila
study strongly indicates speciﬁc genetic interplay between
the MMP and FMRP pathways that should be the focus
of investigation in the immediate future [53]. It will be
important to fully study the roles of TIMP and MMPs in the
context of synaptic development/reﬁnement and to deﬁne
overlapping and distinct synaptic functions of the dif-
ferent MMP family members (i.e., membrane-anchored
versus secreted). Moreover, a great limitation in the recent
Drosophilastudywasthatitonlyexaminedsynapticstructure
defects, and it is imperative to extend the work to the
examination of minocycline/MMP involvement at the level
of synaptic function/plasticity and behavioral outputs in the
Drosophila FXS model. Besides the neuronal mechanisms, it
is also important to note that the genetic interaction between
MMPandFMRPoccursalsoinnonneuronaltissues,because
MMP-1 nonneuronal phenotypes and overall lethality are
rescued by dFMR1 removal [53]. A similar nonneuronal
FMR1 function is also revealed by the joint symptoms of
FXSpatients,stronglyimplicatinganECMcomponentofthe
human disease state. Moving forward, it will be important
to understand how TIMP/MMP dysfunction ﬁts into the
larger picture of FXS pathogenesis, to provide both a greater
understanding of TIMP/MMP roles at the synapse, as well as
to bring to light possible new therapeutic targets for FXS.
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